Lophatananon Artitaya, Stewart-Brown Sarah, Kote-Jarai Zsofia, Olama Ali Amin Al, Garcia Sara Benlloch, Neal David E, Hamdy Freddie C, Donovan Jenny L, Giles Graham G, Fitzgerald Liesel M, Southey Melissa C, Pharoah Paul, Pashayan Nora, Gronberg Henrik, Wiklund Fredrik, Aly Markus, Stanford Janet L, Brenner Hermann, Dieffenbach Aida K, Arndt Volker, Park Jong Y, Lin Hui-Yi, Sellers Thomas, Slavov Chavdar, Kaneva Radka, Mitev Vanio, Batra Jyotsna, Spurdle Amanda, Clements Judith A, Easton Douglas, Eeles Rosalind A, Muir Kenneth
Centre of Epidemiology, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Medicine and Health, The University of Manchester, Manchester M13 9PL, UK.
Division of Health sciences, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.
Br J Cancer. 2017 Aug 22;117(5):734-743. doi: 10.1038/bjc.2017.231. Epub 2017 Aug 1.
Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.
We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.
The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.
There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.
关于身高与前列腺癌风险的证据并不一致，然而，最近基于大数据集的研究支持身高与侵袭性前列腺癌风险之间可能存在关联。
我们分析了来自PRACTICAL联盟的数据，该联盟包括6207例前列腺癌病例和6016例对照以及一个高级别病例子集（2480例）。我们探讨了身高、与生长过程相关基因的多态性作为主要影响因素及其可能的相互作用。
结果表明身高与高级别前列腺癌风险相关。身高>180 cm的男性与身高<173 cm的男性相比，风险增加22%（比值比1.22，95%置信区间1.01 - 1.48）。生长途径基因中的遗传变异与前列腺癌风险相关。所选变异的综合得分显示，与最低得分组相比，最高得分组中总体前列腺癌和高级别前列腺癌的风险分别显著增加13%和15%。
没有证据表明身高与所选候选单核苷酸多态性之间存在基因 - 环境相互作用。我们的研究结果表明身高在高级别前列腺癌中发挥作用。与生长相关基因中的遗传变异对所有病例和高级别前列腺癌都有影响。这两种暴露因素之间不存在相互作用。
